GH Research (NASDAQ:GHRS) Issues Quarterly Earnings Results

GH Research (NASDAQ:GHRS) issued its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06, FiscalAI reports.

GH Research Price Performance

Shares of GHRS stock opened at $15.93 on Friday. GH Research has a one year low of $7.98 and a one year high of $19.51. The company’s fifty day moving average price is $15.45 and its 200-day moving average price is $14.24. The company has a market capitalization of $828.84 million, a price-to-earnings ratio of -19.91 and a beta of 1.00.

Key Stories Impacting GH Research

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company business update — GH Research reported full‑year 2025 results and said it completed the Phase 2b GH001 trial in treatment‑resistant depression, presented the dataset at major conferences, and received FDA clearance to begin U.S. clinical investigations; the company also reported cash and marketable securities of $280.7M, which supports upcoming development programs. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly beat — GH Research reported EPS of ($0.23) vs. consensus ($0.29), surprising modestly to the upside, which likely helped lift sentiment. Quarterly press release
• Positive Sentiment: Analyst price‑target upgrades — Citizens JMP raised its target to $42 with a “market outperform” rating and Needham raised its target to $32 with a “buy” rating; separate coverage also shows a $70 target reported in the market press (HC Wainwright). These upgrades increase upside expectations and likely contributed to buying interest. Analyst upgrades (Benzinga) Needham PT raise Price target to $70 note
• Neutral Sentiment: Market commentary — Coverage noting GHRS activity across Nasdaq futures and broader market focus may amplify volatility but is not specific new corporate information. Kalkine Media article
• Neutral Sentiment: Short interest data appears non‑informative in recent reporting (shows 0 shares), so it does not appear to be a driver of current price action. (Reported days‑to‑cover is 0.0.)
• Negative Sentiment: HC Wainwright earnings revisions — Although HC Wainwright retains a “Buy” rating and a $70 target, the firm reduced near‑term EPS forecasts for FY2025–FY2028 (more negative near‑term EPS path), which introduces risk around timing and magnitude of commercialization and could temper upside. HC Wainwright comments

Institutional Investors Weigh In On GH Research

Institutional investors have recently bought and sold shares of the business. RTW Investments LP raised its holdings in GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock valued at $75,359,000 after acquiring an additional 364,251 shares during the period. Lynx1 Capital Management LP boosted its stake in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the period. Barclays PLC boosted its stake in shares of GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after acquiring an additional 822 shares during the period. Osaic Holdings Inc. grew its position in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after purchasing an additional 10,600 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Analyst Upgrades and Downgrades

GHRS has been the subject of several analyst reports. TD Cowen restated a “buy” rating on shares of GH Research in a research note on Monday, January 5th. Canaccord Genuity Group boosted their price target on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Thursday, January 22nd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.